A股異動丨腦機接口概念股普漲 國際醫學漲停,三博腦科漲4.5%
腦機接口概念股普遍上漲,其中,漢威科技漲超16%領銜,國際醫學、高德紅外、航天發展漲停,嘉禾智能、創新醫療漲超7%,三博腦科、翔宇醫療漲4.5%,南京熊貓、科大智能、中科信息跟漲。消息上,上海階梯醫療科技有限公司日前宣佈完成3.5億元B輪融資,用於推動腦機接口產品的臨牀試驗、新一代技術研發以及醫療級MEMS生產基地建設。該融資是中國植入式腦機接口行業的最大一筆,顯示出資本對腦機接口技術的高度認可,有望加速行業商業化進程。近年來,腦機接口在醫療領域備受資本青睞,推動了技術研發與臨牀應用。據麥肯錫測算,全球腦機接口醫療應用的潛在市場規模在2030年至2040年有望達到400億美元至1450億美元。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.